Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

The alliance has focused on the addition of Mallya to Novo Nordisk’s FlexTouch pen injector for insulin delivery, with a third partner – Healthy2Sync – brought on board earlier this year to ...

For Novo Nordisk, a company still rooted in principles ... glucose levels and other markers via connected devices and insulin pens. Many cloud-connected continuous glucose meters, and patient ...

Pictured is an insulin pen manufactured by the Novo Nordisk company on March 14, 2023, in Miami, Florida. The pharmacy benefit managers, the middlemen between manufacturers and insurance companies ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...